Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Proteasome01:13

The Proteasome

1.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.5K
The Proteasome02:18

The Proteasome

9.9K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.9K
The Proteasome02:18

The Proteasome

4.2K
4.2K
The Proteasome Structure01:17

The Proteasome Structure

1.5K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
1.5K
Regulated Protein Degradation02:58

Regulated Protein Degradation

8.6K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.6K
Proteomics01:33

Proteomics

9.1K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intratumoral microbiota and host genotype cooperatively shape neutrophil cytotoxic functions in colorectal cancer.

Cell host & microbe·2026
Same author

A Spinster-like Transporter at the Inner Membrane Complex is critical for Toxoplasma gondii cytokinesis, motility and invasion.

PLoS pathogens·2026
Same author

Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer.

Cell reports·2025
Same author

TRIM24 as a therapeutic target in endocrine treatment-resistant breast cancer.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

The impact of stenosis treatment on the hemodynamic crosstalk between carotid arteries.

Scientific reports·2025
Same author

An integrated proteomic portrait of prostate cancer progression.

Cell reports·2025

Related Experiment Video

Updated: Dec 23, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

4.3K

Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology.

Carlotta Cecchini1, Sébastien Tardy2, Valentina Ceserani2

  • 1School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, CH-1206 Geneva;,

Chimia
|April 26, 2020
PubMed
Summary

Dysregulated ubiquitylation drives cancer. Proteolysis Targeting Chimeras (PROTACs) offer a novel strategy to degrade oncogenic proteins, potentially counteracting Von Hippel-Lindau (VHL) deficient renal cell carcinoma (RCC).

More Related Videos

Ubiquitin Chain Analysis by Parallel Reaction Monitoring
08:33

Ubiquitin Chain Analysis by Parallel Reaction Monitoring

Published on: June 17, 2020

3.9K
Detection of Protein Ubiquitination Sites by Peptide Enrichment and Mass Spectrometry
11:54

Detection of Protein Ubiquitination Sites by Peptide Enrichment and Mass Spectrometry

Published on: March 23, 2020

10.1K

Related Experiment Videos

Last Updated: Dec 23, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

4.3K
Ubiquitin Chain Analysis by Parallel Reaction Monitoring
08:33

Ubiquitin Chain Analysis by Parallel Reaction Monitoring

Published on: June 17, 2020

3.9K
Detection of Protein Ubiquitination Sites by Peptide Enrichment and Mass Spectrometry
11:54

Detection of Protein Ubiquitination Sites by Peptide Enrichment and Mass Spectrometry

Published on: March 23, 2020

10.1K

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Dysregulated ubiquitylation and oncogenic substrate accumulation contribute to tumorigenesis.
  • Mutations in Von Hippel-Lindau (VHL) E3 ubiquitin ligase lead to overexpression of hypoxia-inducible factors (HIF-1α and HIF-2α), driving renal cell carcinoma (RCC) development.
  • Targeting 'undruggable' proteins with conventional small molecules is challenging.

Purpose of the Study:

  • To explore Proteolysis Targeting Chimeras (PROTACs) as a novel therapeutic strategy.
  • To investigate the potential of PROTACs in inducing selective protein degradation.
  • To understand the Ubiquitin-Proteasome System (UPS) in the context of VHL-deficient RCC.

Main Methods:

  • The study presents a working hypothesis based on the principles of PROTAC technology.
  • Focuses on the mechanism of targeted protein degradation via the UPS.
  • Explores the application of PROTACs to counteract VHL-deficient RCC.

Main Results:

  • PROTACs offer an alternative to traditional drug discovery by inducing protein degradation rather than enzyme inhibition.
  • This approach addresses limitations associated with targeting 'undruggable' proteins.
  • PROTACs demonstrate potential for selective degradation of oncogenic substrates implicated in RCC.

Conclusions:

  • Proteolysis Targeting Chimeras (PROTACs) represent a promising strategy for targeted protein degradation.
  • This approach could overcome challenges in treating cancers with 'undruggable' targets, such as VHL-deficient RCC.
  • Further research into the UPS and PROTACs is warranted to develop novel cancer therapies.